John Weinman1, Selina Graham2, Martha Canfield3, Maria Kleinstäuber4, Anna I Perera4, Nicola Dalbeth5, Keith J Petrie4. 1. Institute of Pharmaceutical Sciences, Kings College London, UK. Electronic address: john.weinman@kcl.ac.uk. 2. Institute of Pharmaceutical Sciences, Kings College London, UK. 3. Institute of Psychiatry, Psychology & Neuroscience, Kings College London, UK. 4. Department of Psychological Medicine, University of Auckland, New Zealand. 5. Department of Medicine, University of Auckland, New Zealand.
Abstract
OBJECTIVE: Adherence continues to be a major challenge in healthcare but there is still limited understanding of all the factors which can influence adherence behaviour. The present study was designed to identify a range of factors associated with intentional non-adherence and to see if they could be formed into a psychometrically sound scale. METHODS: Patients in three different clinical groups (Hypertension (N = 175); Oncology (N = 115); Gout (N = 196)) were given the new scale together with an adherence self-report and/or biomarker measure. Other, more established measures of factors known to be associated with adherence (BMQ, PAM, BIPQ), were also completed by patients for comparative and validation purposes. Exploratory Factor Analysis (EFA) was conducted to examine the factor structure of the new scale, and other statistical analyses were used for testing the psychometric properties of the new scale. RESULTS: EFA revealed two factors, which were labelled "Resisting illness" and "Testing treatment". Both scales were found to have good psychometric properties and explained unique variance in adherence in all three clinical groups. CONCLUSION: This new scale shows promise in describing and explaining some relatively novel factors underlying treatment non-adherence. Further work in different patient groups and clinical contexts is needed to confirm the factor structure and predictive value of these scales.
OBJECTIVE: Adherence continues to be a major challenge in healthcare but there is still limited understanding of all the factors which can influence adherence behaviour. The present study was designed to identify a range of factors associated with intentional non-adherence and to see if they could be formed into a psychometrically sound scale. METHODS:Patients in three different clinical groups (Hypertension (N = 175); Oncology (N = 115); Gout (N = 196)) were given the new scale together with an adherence self-report and/or biomarker measure. Other, more established measures of factors known to be associated with adherence (BMQ, PAM, BIPQ), were also completed by patients for comparative and validation purposes. Exploratory Factor Analysis (EFA) was conducted to examine the factor structure of the new scale, and other statistical analyses were used for testing the psychometric properties of the new scale. RESULTS: EFA revealed two factors, which were labelled "Resisting illness" and "Testing treatment". Both scales were found to have good psychometric properties and explained unique variance in adherence in all three clinical groups. CONCLUSION: This new scale shows promise in describing and explaining some relatively novel factors underlying treatment non-adherence. Further work in different patient groups and clinical contexts is needed to confirm the factor structure and predictive value of these scales.
Authors: Vahid Yazdi-Feyzabadi; Nouzar Nakhaee; Mohammad Hossein Mehrolhassani; Soheila Naghavi; Enayatollah Homaie Rad Journal: BMC Health Serv Res Date: 2021-02-12 Impact factor: 2.655
Authors: Henryka Homętowska; Natalia Świątoniowska-Lonc; Jakub Klekowski; Mariusz Chabowski; Beata Jankowska-Polańska Journal: Int J Environ Res Public Health Date: 2022-09-14 Impact factor: 4.614
Authors: Natalia Świątoniowska-Lonc; Jacek Polański; Grzegorz Mazur; Beata Jankowska-Polańska Journal: Int J Environ Res Public Health Date: 2021-03-10 Impact factor: 3.390